HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland.

Abstract
The protein tyrosine phosphatase non-receptor 22 (PTPN22) 1858 C>T poly-morphic variant gene (rs2476601) displays an association with systemic lupus erythematosus (SLE) and other autoimmune diseases. However, its contribution to SLE has been found to be disputable. We therefore examined the association of PTPN22 1858 C>T polymorphism with susceptibility to SLE in the Polish population, among patients with SLE (n=150) and controls (n=300). We found a contribution of the PTPN22 1858 C>T polymorphism to the incidence of SLE. Women with the PTPN22 TT and PTPN22 CT genotypes displayed a 2.016-fold increased risk of SLE (95% CI=1.324 - 3.070, P=0.0014). However, we did not observe an increased risk for the homozygous PTPN22 TT genotype OR= 2.552 (95% CI=0.6748-9.64, p=0.1675). Our results confirm an association of the 1858 C>T polymorphism of the PTPN22 gene with SLE, which was previously observed in other populations.
AuthorsP Piotrowski, M Lianeri, M Wudarski, J K Lacki, P P Jagodziński
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2008 Nov-Dec Vol. 26 Issue 6 Pg. 1099-102 ISSN: 0392-856X [Print] Italy
PMID19210878 (Publication Type: Journal Article)
Chemical References
  • PTPN22 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22
Topics
  • Adult
  • Female
  • Genetic Predisposition to Disease (epidemiology)
  • Genotype
  • Humans
  • Lupus Erythematosus, Systemic (epidemiology, genetics)
  • Middle Aged
  • Point Mutation
  • Poland (epidemiology)
  • Polymorphism, Genetic
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22 (genetics)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: